Transcriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn's disease patients by Gareth Marlow et al.
Marlow et al. Human Genomics 2013, 7:24
http://www.humgenomics.com/content/7/1/24PRIMARY RESEARCH Open AccessTranscriptomics to study the effect of a
Mediterranean-inspired diet on inflammation in
Crohn's disease patients
Gareth Marlow1,2, Stephanie Ellett1,2, Isobel R Ferguson1, Shuotun Zhu3, Nishi Karunasinghe3,
Amalini C Jesuthasan1,2, Dug Yeo Han1,2, Alan G Fraser2,4 and Lynnette R Ferguson1,2*Abstract
Background: Inflammation is an essential immune response; however, chronic inflammation results in disease
including Crohn's disease. Therefore, reducing the inflammation can yield a significant health benefit, and one way
to achieve this is through diet. We developed a Mediterranean-inspired anti-inflammatory diet and used this diet in
a 6-week intervention in a Crohn's disease population. We examined changes in inflammation and also in the gut
microbiota. We compared the results of established biomarkers, C-reactive protein and the micronuclei assay, of
inflammation with results from a transcriptomic approach.
Results: Data showed that being on our diet for 6 weeks was able to reduce the established biomarkers of
inflammation. However, using transcriptomics, we observed significant changes in gene expression. Although no
single gene stood out, the cumulative effect of small changes in many genes combined to have a beneficial effect.
Data also showed that our diet resulted in a trend of normalising the microbiota.
Conclusions: This study showed that our Mediterranean-inspired diet appeared to benefit the health of people
with Crohn's disease. Our participants showed a trend for reduced markers of inflammation and normalising of the
microbiota. The significant changes in gene expression after 6 weeks highlighted the increased sensitivity of using
transcriptomics when compared to the established biomarkers and open up a new era of dietary intervention
studies.
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Nutrigenomics studies the effect of a specific food or diet
on gene and expression using the omic technologies. This
will lead to a better understanding of the mechanism of
how specific dietary components affect specific gene and
proteins resulting in an understanding of how metabolism
is influenced [1].
Determining the effects of intervention studies can be
difficult, as the change in gene expression for an individ-
ual gene may be low but the number of genes affected
could be large, resulting in a cumulative beneficial effect* Correspondence: l.ferguson@auckland.ac.nz
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stated.as a result of the intervention. Such trials are costly and
time consuming and have required a prior hypothesis
and ideally pilot data before commencement, to ensure
that the correct genes were measured. The technology
of transcriptomics has allowed non-hypothesis-based
studies to be undertaken. This technique allows the
study of thousands of genes simultaneously, and the sensi-
tivity allows the detection of a small change in the expres-
sion of a gene. The other advantage of such a sensitive
technique is that the results allow intervention trials to be
conducted over a much shorter time frame and with fewer
participants. The non-hypothesis-based approach and the
reduced cost of a shorter smaller trial would allow smaller
food companies to prove efficacy of functional foods or
novel diets and thus make a substantiated health claim.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Table 1 The relative abundance of bacteria in a healthy




Bacteroidetes Approximately 25 Decreased expression
Firmicutes Approximately 65 Decreased expression in Clostridium
clusters IV and XIVa and increased
expression in Bacillus
Actinobacteria Approximately 5
Proteobacteria Approximately 8 Increased expression
Fusobacteria Approximately 1
Verrucomicrobia Approximately 2
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chronic inflammation can lead to chronic diseases in-
cluding cardiovascular disease, rheumatoid arthritis,
Alzheimer's, Crohn's disease and even some cancers
[2-4]. Therefore, reducing the inflammation can yield a
significant health benefit [2,5,6]. Crohn's disease is a
chronic intestinal disorder, typified by chronic inflam-
mation of the gastrointestinal tract. While it has a clear
genetic susceptibility, lifestyle factors including diet are
important factors in disease development [7-9]. If diet is
a cause of symptoms, then it stands to reason that diet
can also relieve symptoms, and therefore, Crohn's disease
would be a good target for nutrigenomics [1,10].
As Crohn's disease is localised to the gastrointestinal
tract, one would expect to find dysbiosis of the intestinal
microbiome [11-13]. The interplay between diet, intestinal
microbiota, genetics and health is complex [14]. In recent
years, the role of the microbiota has become of greater
importance in understanding human health and disease.
Six bacterial phyla, comprising over 1,000 species, have
been identified as the predominant inhabitants of the hu-
man gut [15,16]. While previously considered a static en-
tity, it is now emerging that the ratio of the bacterial phyla
and species in the gut is constantly changing in response
to external influences like diet. Different diseases also have
a deviation from what is being considered a ‘normal’ ratio
of bacterial phyla [17]. Whether change to the microbiota
is a cause or effect of disease is currently unknown.
A healthy intestinal mirobiome consists of six bacterial
phyla—Firmicutes, Bacteroidetes, Actinobacteria, Proteo-
bacteria, Fusobacteria and Verrucomicrobia, with species
of Firmicutes and Bacteriodetes being the most abundant
at approximately 65% and 25%, respectively. Variations are
observed in healthy individuals by the abundance of the
different species within each phylum; however, disease
association is observed by variations in the abundance
of the six phyla [18]. Manichanh [19] and Sokol [20]
both reported a reduction in faecal microbial diversity of
patients with Crohn's disease, particularly a reduction in
the number of species of the phyla Firmicutes (specifically
Clostridium clusters IV and XIVa) and Bacteroidetes, with
a corresponding increase in Proteobacteria and Bacillus
[21] (Table 1). We developed an anti-inflammatory diet
based upon a Mediterranean-inspired diet, which is
well-known for its protective ability towards chronic
disease [2,5,22-26]. To this base diet, we added foods
that previous research has shown to be beneficial in re-
ducing inflammation and removed foods that are known
to be detrimental to Crohn's disease patients [27,28].
We conducted a pilot study in early 2012 [29], using
both the established validated biomarkers, C-reactive
protein (CRP) [30,31] and micronucleus assay (MN)
[32], and transcriptomics to test the ability of this
Mediterranean-inspired diet to reduce inflammation inhealthy people [29]. Based on the success of this trial as
determined by a statistically significant reduction in
CRP in this healthy group, a similar trial was under-
taken in participants with Crohn's disease. In this sec-
ond study, we hoped to prove that the diet reduced
inflammation and was beneficial to patients with
Crohn's disease. We also hoped to show that the tran-
scriptomic technique was more sensitive and thus re-
quired fewer subjects over a shorter time frame than
the established biomarkers [5,33,34].
Results
Adherence to the diet
All eight participants completed the 6-week diet and in
a self-reported questionnaire felt they adhered to the
diet well. Based on participant responses to the food
diaries, we were able to show that the average total
energy consumption reduced from 8,189 to 6,716 kJ, and
cholesterol levels were reduced by 20%. There was also a
reduction in average intake of saturated fat (43.9% to
32.1%) and a corresponding increase in mono- (38.9% to
46.6%) and poly-unsaturated fats (17% to 21.1%).
Biomarkers
The established biomarkers, CRP and micronuclei num-
bers, showed a trend of reduction after the 6-week diet;
however, this was not significant. The change in CRP level
as a result of dietary intervention is shown in Figure 1.
Overall, there was a reduction after the 6-week diet, but
this was not statistically significant (p = 0.39). Cytokinesis-
blocked micronuclei numbers before and after dietary
intervention are shown in Figure 2. Although numbers
decreased after intervention, this reduction did not
reach statistical significance (p = 0.15).
Gene expression
Using the Affymetrix PrimeView™ microarray (Santa Clara,
CA, USA), we found that gene expression was significantly
affected (Figure 3). In total, we found that 3,551 genes had
significantly (p < 0.05) altered expression as a result of the
Figure 1 Mean (±SE) levels of C-reactive protein pre- and
post-dietary intervention for each participant. Figure 3 Differential expression of top 100 genes (p < 0.002)
pre- and post-dietary intervention. Based on analysis of the top
differentially expressed transcripts, it is clear that transcription
expression is changed over time, with expression being both
increased (red) and decreased (green) significantly in just 6 weeks.
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and 1,649 down-regulated. These results highlight the
increased sensitivity in this methodology.
Just changing gene expression is of no benefit; we ex-
pect our diet to change inflammation-relevant genes.
We used pathway analysis software (Ingenuity Pathway
Analysis (IPA)) to examine these differentially expressed
genes in more detail. Table 2 shows the top functions
and the number of differentially expressed genes for
each. The functions were grouped into three categories
by IPA: (1) diseases and disorders, (2) molecular and cel-
lular function and (3) physiological system development
and function.
Table 3 summarises the significantly affected canonical
pathways for the dietary intervention, calculated by IPA.Figure 2 Mean (±SE) micronuclei scored in 1,100 cytokinesis-
blocked cells for each participant pre- and post-dietary
intervention.The results are ranked according to significance (Fischer's
exact test). The ratio for each pathway is also given. The
ratio is the number of genes in the dataset that are in the
canonical pathway divided by the total number of genes in
that pathway.
In order to better understand the connections between
the differentially regulated genes, we mapped the genes
into a network diagram based on interactions as deter-
mined by the IPA Knowledge Base, using the upstream
regulator interferon regulatory factor 2 (IRF2) (Figure 4).
IRF2 has been shown to regulate NF-κB activity, which
is essential in control of immune response and inflam-
mation [35] and within the network to indirectly interact
with signal transducer and activator of transcription 3
(STAT3). STAT3 is an important transcription factor in
the JAK/STAT pathway and has been shown to be affected
in inflammatory bowel disease (IBD) [36,37].
Microbiota abundance
The expression of the six bacterial phyla of the study
participants was not too dissimilar from the healthy
specimens (Figure 5) or from the theoretical diversity of
a normal microbiome. However, before the diet, there
was a tendency towards a reduction in bacterial diver-
sity, indicative of Crohn's disease. This is noted by a
combined relative abundance of Bacteroidetes at 17.89%
in the study participants compared to 22.64% in the
healthy individuals, Bacillaceae at 4.65% compared to
3.44% in the healthy individuals and a 5.93% relative
abundance of Proteobacteria in the study participants
compared to 1.67% in the healthy individuals. The
Table 2 Key functions associated with dietary intervention
Top function Number of genes p value
Diseases and disorders
Neurological disease 122 8.67E − 09 to 9.70E − 03
Skeletal and muscular disorders 138 8.67E − 09 to 7.60E − 03
Infectious disease 126 8.67E − 08 to 1.41E − 02
Psychological disorders 91 1.27E − 05 to 9.70E − 03
Cancer 358 1.37E − 05 to 1.37E − 02
Molecular and cellular function
Cellular growth and proliferation 218 1.23E − 07 to 1.47E − 02
Cellular development 177 1.81E − 07 to 1.40E − 02
Cell cycle 84 9.24E − 07 to 1.24E − 02
Cell-to-cell signalling and interaction 108 1.76E − 06 to 1.46E − 02
Cellular movement 120 1.76E − 06 to 1.37E − 02
Physiological system development and function
Hematological system development and function 136 1.76E − 06 to 1.40E − 02
Immune cell trafficking 66 1.76E − 06 to 1.24E − 02
Tissue development 124 1.76E − 06 to 1.46E − 02
Organismal survival 154 3.81E − 06 to 3.81E − 06
Cardiovascular system development and function 110 3.90E − 06 to 1.32E − 02
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the study group (72.8%) and the healthy individuals (73%).
When combining all data from Crohn's disease partici-
pants (n = 8) and making pre- and post-diet comparisons
of each bacterial cluster, there is a forward trend, yet no
significant improvement in the expression of the bacteria
that were known to have an altered relative abundance in
Crohn's disease (Figure 5). There was an increase in
the expression of Bacteroidetes (17.89% to 18.74%),
Clostridium cluster IV (19.2% to 21.86%) and Clostridium
cluster XIVa (26.78% to 28.79%) and a decrease in the
abundance of Proteobacteria (5.93% to 5.48%) and
Bacillaceae (4.65% to 4.21%).
Discussion
As previously stated, inflammation can cause chronic
disease; therefore, it is important to identify and reduce
inflammation, one such way is through diet. We found
that in this pilot study, there was a small reduction in
the established biomarkers of inflammation after con-
suming our diet for 6 weeks. Using the transcriptomicTable 3 Key canonical pathways affected by intervention
Name p value Ratio
EIF2 signalling 4.24E − 04 17/200 (0.085)
B cell development 9.31E − 04 6/33 (0.182)
T helper cell differentiation 3.55E − 03 8/72 (0.111)
Uracil degradation II (reductive) 7.6E − 03 2/11 (0.182)
Thymine degradation 7.6E − 03 2/11 (0.182)approach, we did see significant changes in gene expres-
sion. In total, we found 3,551 genes that were differentially
expressed in our study as a result of a 6-week dietary
intervention. The most common candidates were not the
genes that were affected, and although results for indi-
vidual genes were not spectacular, it is the combination
of affected genes that is interesting. The data highlighted
the difference in sensitivity between the established bio-
markers and the transcriptomic approach and confirmed
that conducting a short-term trial with a small number of
participants is feasible.
The patients who volunteered for this study were selected
based on strict criteria. Several of them already used diet as
a way of controlling symptoms and so for transcriptomics
to still show an effect highlights how sensitive this tech-
nique is. This increased sensitivity allows for short-term
studies with fewer study numbers than traditional trials to
be performed, which has significant implications for future
human clinical trials.
The ratio of the six bacterial phyla or families from the
faecal microbiome of healthy individuals has been deter-
mined. It is well documented that deviation from this
‘norm’ occurs in individuals who have Crohn's disease.
Normalising the intestinal microbiota through diet is a
step towards potentially reducing inflammation and thus
restoring health and improving the quality of life for
people with Crohn's disease.
After 6 weeks on our Mediterranean-inspired diet, there
was some ‘normalising’ of the intestinal microbiota. As
previously stated, the participants were already managing
Figure 4 Generation of a biological network of genes related to the upstream regulator IRF2. Network was generated by IPA. Connections
were applied based on known interactions within the Ingenuity Pathway Knowledge Base. Solid lines between genes represent direct interactions
and the dashed lines indirect. Genes are represented by nodes, with the red and green colours indicating up- or down-regulated expression; the
greater the colour intensity, the higher the level of differential expression.
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biota was not too dissimilar from that documented in a
healthy group. However, as a group, the microbiota before
the diet was tending towards that expected for people with
Crohn's disease, notably a reduction in the presence of
Bacteroidetes and an increase in the presence of Proteo-
bacteria and Bacillaceae.Figure 5 Relative abundance of microbiota pre- and post-dietary interveConsuming the Mediterranean-inspired anti-inflammatory
diet for 6 weeks was able to influence the intestinal micro-
biota of our study population, although this improvement
should be noted as a forward trend rather than any statis-
tically significant change. There was an observed increase
in Bacteroidetes and the Clostridium clusters and a de-
crease in Protebacteria and Bacillaceae.ntion. Healthy samples (n= 2), CD pre-diet (n= 8) and CD post-diet (n= 8).
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One of the aims of this pilot study was to compare the
data obtained from traditional biomarkers of inflammation
with that of transcriptomics. The Affymetrix GeneChip®
PrimeView™ arrays were selected as they provide complete
coverage of the human genome. We were impressed by
the increased sensitivity provided by the arrays over the
biomarkers.
Peripheral blood mononuclear cells (PBMCs) can be
easily obtained from a venepuncture, which allows for
easy and repeated collection unlike biopsies of other
tissues [38]. PBMCs have been used to examine gene
expression in numerous diseases including inflammation
[39-45] and have also been shown to act as a biomarker
of nutritional interventions [22,46,47] and used to predict
inflammatory response to functional foods [48]. The in-
creased sensitivity of transcriptomics and the fact that
PBMCs can be used as a model to study the expression of
inflammatory genes [40] make this methodology attractive
for non-hypothesis-based studies.
One of the drawbacks of this study was the small study
population, which resulted in observing a trend in effect
of the diet rather than significant results. However, one
of the benefits of using transcriptomics is the ability to
conduct dietary interventions over a shorter time frame
and requiring fewer subject numbers. This subsequently
reduce costs which will open up the area of health-based
food claims to a wider market, meaning that more com-
panies and more products could be tested. This could lead
to a better understanding of the mechanism of action and
thus substantiated health claims benefiting both the
companies and the population.
The data from this pilot study, although not significant,
does highlight that by choosing an anti-inflammatory diet,
even for a short time, can have an effect on reducing
inflammatory markers, changing gene expression and
normalising the microbiota.Methods
Study design
This study was granted ethical approval by the Northern
Regional Ethics Committee of New Zealand (reference
NTY/11/11/109). Requirements for inclusion in the
study were very strict and were intentionally so given
the aetiology of Crohn's disease and the potential bias
from medication and surgical interventions. Selection
criteria included the following: had no bowel surgery,
was not taking prednisone or similar anti-inflammatory
medication, had no changes to their medication over the
last 3 months, indicating a stable condition, were willing
to provide samples at the beginning and end of the study
and were willing to change their diet. This was self-
reported by the participants.All participants consumed the Mediterranean-inspired
anti-inflammatory diet for 6 weeks. They were provided
with food items including salmon, organic avocados,
kumara, a variety of vegetables, gluten-free bread, New
Zealand extra virgin olive oil, green tea, honey and fish
oil capsules. The majority of these foods were grown
and produced in New Zealand and were used to supple-
ment the participant's diet. A reduction in the con-
sumption of red meat, white flour, high-fat foods and
sugar was also expected. All participants provided a
blood and faecal sample at the beginning and end of the
study and completed food diaries.
Subject selection/eligibility
Eight participants, from Auckland, New Zealand, who
had active yet stable Crohn's disease symptoms and
passed the selection criteria (see above) were selected to
participate following an initial invitation to all Crohn's
disease participants in the Diet and Gene Database
administered by Nutrigenomics New Zealand.
Our participants were six females and two males, aged
between 31 and 60 years (mean age 45.4 years), and the
length of time since diagnosis with Crohn's disease
ranged from 7 to 36 years.
Study outcomes
Levels of C-reactive protein, a systemic measure of inflam-
mation [31] and changes in DNA damage in peripheral
blood lymphocyte cells by the micronucleus assay (in
accordance with OECD guidelines 487) were scored
before and after the diet, along with comparisons of
RNA gene expression profiles.
C-reactive protein
A blood sample collected in serum-separating tubes was
analysed for C-reactive protein. C-reactive protein is
found in the blood in response to inflammation and is a
biomarker for potential disease development. Specimens
were analysed by a medical testing laboratory, Labtests
Auckland, according to their protocols for the latex-
enhanced immunoturbidimetric assay.
DNA damage—micronucleus assay
The cytokinesis-block micronucleus assay [32], a validated
method for determining DNA damage in peripheral blood
lymphocytes cells, was used to observe any changes in
DNA damage before and after the diet intervention. DNA
damage was determined by the presence of micronuclei
(MN) in the cytoplasm of bi-nucleated lymphocyte cells.
Whole blood treated with anticoagulant (heparin) was
collected, stored at room temperature and cultured
within 24 h. Duplicate cultures containing 0.6 ml whole
blood and 9.25 ml alpha MEM and 15% foetal calf
serum (Gibco New Zealand Ltd., Auckland, New Zealand)
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(PHA, Gibco New Zealand Ltd.) was added to stimulate
lymphocyte replication. The cells were incubated in a
humidified incubator containing 5% carbon dioxide for
44 h. Cytochalasin B (Sigma Chemical Co., St. Louis,
MO, USA) was added to give a final concentration of
4.5 μg/ml, and the culture was incubated for an add-
itional 26 h. The cytochalasin B would halt any further
cell growth. Cells were harvested using standard proto-
cols as outlined [49], including centrifugation, swelling
of the cells using hypotonic KCl and fixing in a solution
of methanol and acetic acid before dropping onto slides.
Once dried, the slides were stained with Diff-Quik
(Dade Behring Inc., Sacramento, CA, USA) according to
staining protocols. Two thousand bi-nucleated cells
were scored for micronuclei using the criteria outlined
by Heddle et al. [50] and Fenech [51].
Transcriptomics
RNA isolation and storage
Whole blood was collected in a PAXgene Blood RNA
Tube (PBRT) (PreAnalytiX) following the manufacturer's
recommended protocol. The blood was incubated at room
temperature for 2 h, after collection to improve RNA
yield, before being stored at −70°C.
RNA extraction was performed according to the rec-
ommended protocol PAXgene Blood RNA System Kit
(Qiagen). The quantity of RNA was determined using
the NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA) and the quality of
RNA by the Experion RNA StdSens Analysis Kit (Biorad,
Hercules, CA, USA). For successful gene expression
microarray hybridization, a concentration of >100 ng/μl
of RNA and a RNA quality indicator (RQI) of >8 are
required.
Gene expression arrays
Microarray hybridization was performed on GeneChip®
PrimeView™ Human Gene Expression arrays (Affymetrix)
following the manufacturer's protocol by The Ramaciotti
Centre, University of New South Wales, Sydney, Australia,
using the Affymetrix GeneChip® Instrument System.
Gene expression data analysis
Affymetrix Primeview array data was read using the ‘affy’
package in the statistical language R and normalised
using the RMA method. QA of the data showed that it
was of good quality and free of obvious artifacts or
outliers. The ‘limma’ package was used to compare gene
expression pre- and post-diet, paired by participant code.
Further analyses of the differentially expressed genes,
including network, pathway and functional analysis,
were carried out using IPA (Ingenuity Systems Inc.,
USA; http://www.ingenuity.com).Microbiota analysis
A faecal sample was provided by each study participant
before and after the diet. The samples were frozen
at −80°C until required for analysis. Total DNA from the
faecal matter was extracted according to the protocol
published by Candela et al. [18] in combination with the
DNAeasy Blood and Tissue Kit 50 (Qiagen). The final
DNA concentration and purity were determined using
the NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies). The extracted DNA was standardised to
50 ng/μl and stored at −20°C. These samples were then
sent to the Department of Pharmaceutical Science,
University of Bologna, Italy for analysis. The amplifica-
tion and purification of DNA and the subsequent
HTF-Microbi.Array were conducted according to proto-
cols defined by Candela et al. [18]. Briefly, amplification of
the DNA by PCR was achieved using 16 s rDNA sequen-
cing, facilitated by Taq polymerase (Promega, Madison,
WI, USA) and the universal forward primer f27 (5′-
AGAGTTTGATCMTGGCTCAG-3′) and reverse primer
1492r (5′-TACGGYTACCTTGTTACGACTT-3′). The re-
sultant PCR product was purified using the PCR Clean-up
System Kit (Promega) and concentration of the purified
DNA determined by nanodrop.
Specific detection and quantification of 32 phylogen-
etically related groups of the human intestinal micro-
biome were achieved by the HTF-Microbi.Array, an
adaption to the Ligase Detection Reaction [18]. DNA
probes specific for each of the currently identified bac-
teria of the intestinal microbiome are embedded on the
array slide. Successful hybridisation of the DNA product
to the probe results in fluorescence. The fluorescence
intensities (IF) were normalised to the ligation control
signal and background IF values, removing outlier
signals that were 2.5-fold above or below the average of
the repeated signals (four repeats of each probe on
every array). The results were compared to two healthy
control samples which were obtained at the start of the
study.
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